Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Review article: the effects of antitumour necrosis factor-α on bone metabolism in inflammatory bowel disease.

Veerappan SG, O'Morain CA, Daly JS, Ryan BM.

Aliment Pharmacol Ther. 2011 Jun;33(12):1261-72. doi: 10.1111/j.1365-2036.2011.04667.x. Epub 2011 Apr 26. Review.

2.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
3.

Skeletal morbidity in inflammatory bowel disease.

van Hogezand RA, Hamdy NA.

Scand J Gastroenterol Suppl. 2006;(243):59-64. Review.

PMID:
16782623
4.

Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease.

Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S.

Inflamm Bowel Dis. 2007 Apr;13(4):416-23.

PMID:
17206686
5.

Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease.

Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR.

J Clin Gastroenterol. 2006 Jan;40(1):55-63.

PMID:
16340635
6.

Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.

Lange U, Teichmann J, Müller-Ladner U, Strunk J.

Rheumatology (Oxford). 2005 Dec;44(12):1546-8. Epub 2005 Nov 1.

7.

[Are there any positive effects of TNF-alpha blockers on bone metabolism?].

Seriolo B, Paolino S, Sulli A, Cutolo M.

Reumatismo. 2006 Jul-Sep;58(3):199-205. Italian.

8.

The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.

Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR.

Ann N Y Acad Sci. 2006 Apr;1068:543-56.

PMID:
16831950
9.

The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.

Sandhu A, Alameel T, Dale CH, Levstik M, Chande N.

Aliment Pharmacol Ther. 2012 Jul;36(2):159-65. doi: 10.1111/j.1365-2036.2012.05141.x. Epub 2012 May 23.

10.

Bone density improves with disease remission in patients with inflammatory bowel disease.

Reffitt DM, Meenan J, Sanderson JD, Jugdaohsingh R, Powell JJ, Thompson RP.

Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1267-73.

PMID:
14624148
11.

[Improvement of bone metabolism after infliximab therapy in Crohn's disease].

Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.

Orv Hetil. 2005 Jul 10;146(28):1477-80. Hungarian.

PMID:
16130441
12.

Strategies for targeting tumour necrosis factor in IBD.

Sandborn WJ.

Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):105-17. Review.

PMID:
12617886
13.

Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease.

Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z.

Dig Dis. 2006;24(1-2):201-6.

PMID:
16699279
14.

Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease.

Bultman E, Kuipers EJ, van der Woude CJ.

Aliment Pharmacol Ther. 2010 Aug;32(3):313-23. doi: 10.1111/j.1365-2036.2010.04373.x. Epub 2010 May 22. Review.

15.

Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.

Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M.

Ann N Y Acad Sci. 2006 Jun;1069:420-7.

PMID:
16855169
16.

Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review.

Melek J, Sakuraba A.

Clin Gastroenterol Hepatol. 2014 Jan;12(1):32-44.e5. doi: 10.1016/j.cgh.2013.08.024. Epub 2013 Aug 24. Review.

PMID:
23981521
17.

Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease.

Schulte C, Dignass AU, Mann K, Goebell H.

Inflamm Bowel Dis. 1998 Nov;4(4):268-75.

PMID:
9836078
18.

Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.

El Mourabet M, El-Hachem S, Harrison JR, Binion DG.

Curr Drug Targets. 2010 Feb;11(2):234-41. Review.

PMID:
19916950
19.

Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis.

Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G.

J Intern Med. 2000 Jan;247(1):63-70.

20.

Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study.

Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, Schoon E.

Aliment Pharmacol Ther. 2004 Oct 15;20(8):851-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk